Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Revenue by Segment

Period Ending	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Amvuttra	2.89B	2.31B	1.77B	1.35B	1.09B	970.41M	859.20M	749.30M
Amvuttra Growth	166.66%	138.44%	106.44%	79.78%	66.62%	73.94%	90.43%	128.65%
Collaboration	536.26M	553.37M	619.37M	325.03M	490.83M	510.15M	479.60M	849.70M
Collaboration Growth	9.25%	8.47%	29.14%	-61.75%	-21.87%	-6.60%	-11.25%	497.54%
Givlaari	315.91M	308.49M	286.34M	283.46M	264.71M	255.85M	250.50M	233.60M
Givlaari Growth	19.34%	20.58%	14.31%	21.35%	15.39%	16.72%	21.01%	17.62%
Oxlumo	200.67M	191.44M	185.36M	172.73M	166.46M	166.97M	156.10M	144.60M
Oxlumo Growth	20.55%	14.65%	18.75%	19.46%	29.85%	52.07%	54.71%	63.21%
Royalty	196.53M	174.02M	148.04M	125.23M	107.65M	91.79M	73.40M	59.90M
Royalty Growth	82.56%	89.59%	101.68%	109.07%	140.83%	126.08%	179.09%	213.61%
Onpattro	143.78M	172.79M	197.21M	208.43M	233.09M	252.80M	275.70M	307.00M
Onpattro Growth	-38.32%	-31.65%	-28.47%	-32.11%	-27.45%	-28.71%	-30.69%	-33.43%

Source: Business metrics provided by TipRanks and sourced from official company press releases and documents.